Fumaric Acid

Fumaric Acid

SCHEMBL3268015

CC(C)CN(Cc1sc2ccccc2c1Cl)C1CCNCC1.O=C(O)C=CC(=O)O

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol

The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SLC6A2 known ✓ P23975 20/20 0.65
SLC6A4 known ✓ P31645 18/20 0.65
SLC6A3 known ✓ Q01959 9/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL3268010 1.00 SLC6A2 (0.65) SLC6A2SLC6A4SLC6A3
SCHEMBL3268251 0.91 SLC6A2 (0.59) SLC6A2SLC6A4SLC6A3
Fumaric Acid SCHEMBL3268954 0.90 SLC6A2 (0.64) SLC6A2SLC6A4SLC6A3
Fumaric Acid SCHEMBL3268958 0.90 SLC6A2 (0.64) SLC6A2SLC6A4SLC6A3
Fumaric Acid SCHEMBL3268912 0.81 SLC6A2 (0.68) SLC6A2SLC6A4SLC6A3
Fumaric Acid SCHEMBL3268916 0.81 SLC6A2 (0.68) SLC6A2SLC6A4SLC6A3
SCHEMBL3272243 0.80 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3
Fumaric Acid SCHEMBL5993905 0.79 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3
Fumaric Acid SCHEMBL5993899 0.79 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3
Fumaric Acid SCHEMBL3267493 0.78 SLC6A2 (0.62) SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735302-B1 4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS LILLY CO ELI (US) 2010-06-16 EP disclosed
US-7521462-B2 4-Amino-piperidine derivatives as monoamine uptake inhibitors ELI LILLY AND COMPANY (US) 2009-04-21 US disclosed
US-20070093526-A1 4-Amino-piperidine derivatives as monoamine uptake inhibitors ELI LILLY AND COMPANY (US) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093526-A1 4-Amino-piperidine derivatives as monoamine uptake inhibitors SLC18A2, SLC6A2, SLC6A3 SLC6A2 2/4885SLC6A4 4/4885SLC6A3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.